100 results about "Cyclophosphamide" patented technology

The invention discloses a bran coat polypeptide GR-12 with an immunoregulation function and an application of the bran coat polypeptide GR-12, and the amino acid sequence of the bran coat polypeptide is Gly-Gln-Pro-Trp-Pro-Pro-Ala-Ser-Phe-Ala-Cys-Arg (GQPWPPASFACR, which is called GR-12 for short). Experiments find that the GR-12 can significantly enhance the proliferation activity and phagocytic activity of macrophages RAW264.7 and promote the macrophages RAW264.7 to secrete cytokines; meanwhile, it is found that the GR-12 can significantly enhance the immunomodulatory function of an immunosuppressive mouse induced by cyclophosphamide, specifically, the body weight, thymus index and spleen index of the immunosuppressive mouse are significantly recovered; and the secretion of cytokines and immune globulins in mouse serum is obviously increased. The bran coat polypeptide GR-12 is expected to be further researched and developed into a related medicine product with an immune regulation function, and has a wide application prospect.

The invention belongs to the technical field of biology, and particularly relates to a cryptosporidium parvum infection immunosuppression mouse model and a construction method thereof. Aiming at the problem that the development of cryptosporidiosis drugs and vaccines is seriously limited due to the fact that no model for successfully infecting mice with cryptosporidium parvum exists at present, the invention provides the construction method of the cryptosporidium parvum infection immunosuppression mouse model, which comprises the following steps: firstly, carrying out gavage treatment on the mice for 4-7 days by adopting cyclophosphamide; constructing to obtain an immunosuppressive mouse; feeding PBS (Phosphate Buffer Solution) containing cryptosporidium parvum oocysts through the mouth, and infecting for 7-21 days; and when oocysts are continuously detected from excrement of the mouse and the content of the oocysts is higher than the infection amount, constructing the cryptosporidium parvum infection immunosuppression mouse model. The cryptosporidium parvum infection immunosuppression mouse model is successfully constructed, can be used for subsequent drug and vaccine development tests for cryptosporidium parvum diseases, and has a good application prospect.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses a cyclophosphamide ternary nano-micelle and a preparation method thereof.The cyclophosphamide ternary nano-micelle prepared through the method can be used for treating malignant lymphoma, multiple myeloma, leukemia, breast cancer, ovarian cancer, cervical cancer, prostatic cancer, colon cancer, bronchial cancer, lung cancer and the like. Reasonable preparation steps and a preparation formula are adopted, the use of an organic reagent is reduced, the irritation of cyclophosphamide is reduced and the stability of the micelle is improved by adjusting a freeze-drying technology, and the cyclophosphamide micelle adopts amphiphilic macromolecules as a carrier material, so that the drug loading capacity and the stability of the micelle are obviously improved, and the bioavailability of the micelle is improved. The ternary nano-micelle system has the advantages that the solubility of cyclophosphamide is improved, the in-vivo bioavailability is increased, the preparation method is simple, the micelle performance is stable, and large-scale industrial production is facilitated.

The invention belongs to the technical field of active peptide preparation, and particularly relates to an active collagen peptide with an immunoregulation function and a preparation method and application thereof. The active collagen peptide with an immunoregulation function is prepared by using a method of performing composite enzymolysis and separating and collecting specified collection liquid by using a chromatographic column, and a new thought is provided for improving the immunity; the prepared active collagen peptide can significantly improve the proliferative activity, phagocytic ability and NO secretion amount of RAW264.7 cells and change the cell morphology, has an important regulation effect on immune balance recovery of immunosuppression model mice, and can regulate the problem of low immunologic function of mice induced by cyclophosphamide, regulate immune balance and improve the body immunity.

The invention discloses an outer vesicle of bifidobacterium longum. The outer vesicle is obtained by carrying out anaerobic culture on bifidobacterium longum AY15 through a BS liquid culture medium and then centrifuging. The invention also relates to the effect of the bifidobacterium longum outer vesicle in preparation of drugs for enhancing immune systems and the like. The exovesicles of bifidobacterium longum can change the composition of intestinal flora, influence the metabolism of short-chain fatty acid and activate a short-chain fatty acid receptor, so that the immune system is regulated, the generation of related immune cells is regulated, the balance of the immune cells is promoted, and the immune injury caused by cyclophosphamide is improved.

Provided are nucleic acid molecules encoding mutant Seneca Valley Virus (SVV) that evade neutralizing antibodies with a binding specificity to SVV, as well as nanoparticles containing rapamycin and SVV or mutant SVV. The mutant SVV comprise one or more mutations in one or more SVV epitopes that prevent binding of the mutant SVV to the neutralizing antibodies. The one or more mutations of the mutant SVV may be in one or more SVV epitopes. The epitopes may be inVP1, VP2, and / or VP3 subunits of SVV. Also provided are methods of producing and using the mutant SVV for treating cancer. Also provided are methods of treating a subject comprising administering to the subject the nanoparticles comprising SVV, or mutant SVV, and rapamycin. Also provided are methods of treating a subject comprising administering to the subject SVV or mutant SVV, and cyclophosphamide.

This invention belongs to the fields of biomedicine and cosmetics, and discloses the application of holly glycoside in promoting hair growth and preventing hair loss. Holly glycoside promotes the transition of hair follicles from the telogen phase to the anagen phase (i.e., shortening the telogen phase and prolonging the anagen phase), and inhibits cyclophosphamide-induced apoptosis of hair follicle cells and DHT-induced miniaturization of hair follicles. In androgenetic alopecia, telogen effluvium, and chemical alopecia models, its hair growth-promoting effect is comparable to that of the positive control drug minoxidil. It has broad application prospects in pharmaceutical formulations, cosmetics, skincare products, and beauty products.

The invention discloses a nereis glycopeptide SC2-3 as well as a preparation method and application thereof, and the preparation method comprises the following steps: firstly extracting crude polysaccharide from nereis, and then identifying by means of column chromatography purification, spectroscopy and the like to obtain the nereis glycopeptide SC2-3 with the relative molecular mass of 5061Da. The glycopeptide SC2-3 is obtained by taking nereis as a raw material, and pharmacological experiments show that the nereis glycopeptide SC2-3 has immunomodulatory activity, can improve low mouse immunologic function induced by cyclophosphamide chemotherapeutic drugs, and is expected to be developed into an immunologic adjuvant for assisting in resisting tumors.

This invention provides a method for preparing simian cyclophosphamide, comprising the following steps: loading simian cyclophosphamide extract into a macroporous adsorption resin column, performing first column chromatography using a first eluent to obtain simian cyclophosphamide component; loading the simian cyclophosphamide component into a reversed-phase silica gel column, performing second column chromatography using a second eluent to obtain crude simian cyclophosphamide; and loading the crude simian cyclophosphamide into a gel chromatography column, performing third column chromatography using a third eluent to obtain purified product. This preparation method utilizes a combination of macroporous adsorption resin column, reversed-phase silica gel column, and gel chromatography for purification, along with a specific elution procedure and eluent. The resulting simian cyclophosphamide I has a purity of over 99%, meeting the purity requirements for detection reference standards (>98%) and content determination reference standards (>99%), with an extraction yield of over 50%.

The invention belongs to the technical field of medicines, and particularly relates to a pharmaceutical composition for improving ovarian function damage and degeneration and a preparation method thereof. The invention discloses the GnRH agonist effect of dihydromyricetin DMY for the first time, and the affinity of dihydromyricetin DMY to a GnRH receptor and the GnRH agonist effect of dihydromyricetin DMY are verified through in-vitro experiments. Model animal experiments further prove that the dihydromyricetin DMY has a protective effect on ovarian function impairment caused by chemotherapy. Experiments prove that the dihydromyricetin DMY is given while the cyclophosphamide (CTX) is used for chemotherapy, so that the damage of the dihydromyricetin DMY to the ovarian function during chemotherapy can be reduced, and a protection effect is also achieved on the recovery of the ovarian function after drug withdrawal. The protection effect is reflected on the endocrine function and the reserve function of the ovary, and the preserved ovary reserve function can achieve the pregnancy result after chemotherapy is finished, which indicates that the dihydromyricetin DMY also plays the protection effect on the fertility function of the ovary.

The invention relates to a preparation method and a verification method of deer skin collagen peptide with skin repairing and immunoregulation effects, and belongs to the technical field of biological medicines. The technical problems that the technology for extracting the deer skin collagen peptide from the deer skin of the sika deer is tedious, and whether the prepared deer skin collagen peptide has skin repairing and immunoregulation effects or not are solved. The preparation method of the deer skin collagen peptide with the skin repairing and immunoregulation effects comprises the following steps: cutting deer skin into small pieces, and preparing the deer skin collagen peptide with the molecular weight of less than 10kDa by adopting a double-step enzymolysis method. And a verification experiment of an immunosuppressive mouse is constructed through cyclophosphamide induction. According to the invention, the extraction process is greatly simplified, and a double-step enzymolysis method is adopted, so that the deer skin collagen peptide subjected to enzymolysis is small-molecule peptide, has strong antioxidant capacity, can repair light-damaged cells and promote skin cell growth, and is good in safety; by injecting the deer skin collagen peptide, the immune function of the mouse is improved, and damage caused by mouse cells is relieved.

The utility model discloses cyclophosphamide preparation filling equipment, which belongs to the technical field of filling equipment and comprises a base, a filling component is mounted at the top end of a mounting rack, a fixed end of a stepping motor is mounted at the top end of the mounting rack, and a driving end of the stepping motor penetrates through the mounting rack and is connected with a rectangular mounting plate. The bottom end of the mounting plate is fixedly connected with a driving fixed end of a second electric push rod, the driving end of the second electric push rod is connected with a mounting box, a first screw rod for assisting adjustment is mounted on the inner side of the mounting box, and a servo motor for providing adjustment power for the first screw rod is mounted on the side face of the mounting box; the periphery of the first lead screw is in threaded connection with two symmetrical adjusting rods, the bottom ends of the adjusting rods penetrate through limiting grooves formed in the bottom end of the mounting box and are connected with clamping blocks, and the opposite faces of the two clamping blocks are each provided with an anti-skid pad in an adhesive mode. According to the cyclophosphamide preparation filling equipment, the sealing cover of the filling barrel can be automatically mounted, so that the filling operation is more time-saving and labor-saving.

The invention relates to the technical field of biological medicines, in particular to a maggot alcohol extract for improving chemotherapy immune injury, a preparation method of the maggot alcohol extract and application of the maggot alcohol extract in preparation of medicines, health-care products or functional foods for preventing or treating immune injury caused by chemotherapy medicines. It is found for the first time that the maggot alcohol extract has a remarkable protection effect on immune injury caused by chemotherapeutic drugs such as cyclophosphamide, the number of leukocytes and lymphocytes can be effectively increased, and immune organ atrophy is relieved. The maggot alcohol extract disclosed by the invention can be used for preparing medicines, health care products or functional foods for preventing or treating immune injury caused by chemotherapy, has the characteristics of multiple target spots, high efficiency and low toxicity, is simple and stable in preparation process, and has good development and application prospects.

The present invention relates, in general terms, to a method for treating autoimmune diseases with immunotherapy. The present invention also relates, in general terms, to a method for treating autoimmune diseases comprising administering a cyclophosphamide preconditioning regimen and subsequently administering immunotherapy. TIFF2026514435000017.tif68165

The application discloses a tumor full-nutrition functional emulsion, which comprises the following components in mass: 10-14% of protein, 7-10% of fat, 12-16% of carbohydrate, 0.01-0.02% of vitamin, 0.5-1.0% of mineral substance and 0.5-1% of food additive, and the balance is water; the protein comprises oyster low-molecular peptide and whey protein at a mass ratio of 2-3:8-12; and the food additive comprises Tween 80 and polyglycerol ricinoleate at a mass ratio of 70-75:20-23. The tumor full-nutrition functional emulsion has a water-in-oil-in-water structure and has freeze-thaw stability; after nutrition support of the tumor full-nutrition functional emulsion, the body's immune regulation ability can be significantly enhanced, the side effect of cyclophosphamide chemotherapy can be reduced, and the body's malnutrition and immunosuppression can be effectively improved.

The invention belongs to the technical field of functional foods and health foods, and particularly relates to a composition for improving premature ovarian failure and a preparation method thereof. The composition comprises the following components in parts by weight: 5-15 parts of orange osmanthus pollen, 4-12 parts of flaxseed concentrated powder, 2-8 parts of black-bone chicken peptide, 4-20 parts of rehmannia powder, 2-10 parts of cistanche powder and 1-5 parts of lemon concentrated powder. The composition for improving premature ovarian failure prepared by the invention can reduce the content of follicle stimulating hormone (FSH) and luteinizing hormone (LH) in the serum of a premature ovarian failure rat induced by cyclophosphamide and increase the content of estradiol (E2), thereby achieving the effect of improving premature ovarian failure.

The invention discloses application of exosome-like nanoparticles derived from fructus lycii to preparation of a medicine for preventing or treating oligospermia and / or asthenospermia. Sterile, stable and high-purity fructus lycii exosome-like nanoparticles (LBELNs) are obtained by adopting a differential centrifugation-suction filtration-ultra-high-speed centrifugation method, the physiological efficacy of the LBELNs is researched, and it is found that the LBELNs can significantly improve the oligoasthenospermia disease activity index of male mice induced by cyclophosphamide (CTX); the sperm quantity is obviously increased, the sperm malformation is improved, the sperm motility is improved, and the sex hormone level is recovered. The LBELNs can effectively relieve spermatogenic dysfunction of testicular tissues, the sperm differentiation and formation process is obviously improved, the total number of sperms is increased, and the treatment effect is more obvious along with increase of the dosage of the LBELNs. The invention has potential in preparation of drugs for preventing or treating oligoasthenospermia, and provides a new strategy and treatment method for treating oligoasthenospermia.

The present disclosure provides methods for treating cancer. The methods for treating cancer can include administering pentostatin and cyclophosphamide, followed by administering manufactured T cells. The present disclosure further provides methods for generating such manufactured T cells, the manufactured T cells, and compositions comprising the manufactured T cells.

The invention discloses application of a caenorhabditis elegans reproductive disorder model to screening of strains promoting reproduction health, and relates to the technical field of biologica.Cyclophosphamide medicine intervention is applied to caenorhabditis elegans, so that the normal reproductive system of caenorhabditis elegans is damaged, and the reproductive disorder model is prepared; then 3985 gene knockout strains in an escherichia coli Keio gene knockout library are utilized, and strains with the reproductive capacity remarkably improved for reproductive disorder are screened; and carrying out homologous gene knockout on the probiotics by using a gene editing technology, and screening out the probiotics with the potential of promoting reproductive health. The reproductive disorder model is stable and repeatable, can be used for screening strains or drugs for improving the reproductive function, and also can be used for screening candidate strains or drugs for reducing the reproductive toxicity of cyclophosphamide. According to the method, an effective tool is provided for screening of reproduction-related probiotic strains or screening of related drugs, and meanwhile, the strains screened based on the model provide new candidate strains for treatment and research of reproductive disorder diseases.

The invention belongs to the field of biological pharmacy, and particularly relates to a chalcanthicidin compound and application thereof. The invention discloses a chalcanthicidin compound which is separated from a secondary metabolite of marine actinomycetes Streptomyces sp. KCB-132 (marine actinomycetes sp. KCB-132). Pharmacological activity experiments show that the compound has a moderate inhibition effect on ESKAPE pathogenic bacteria with multiple drug resistance, such as enterococcus faecium, staphylococcus aureus, klebsiella pneumoniae, acinetobacter baumannii and escherichia coli. Therefore, the compound has the potential of being developed into a novel antibacterial agent.

The invention belongs to the technical field of biological medicines, and particularly relates to application of an SIRT5 inhibitor MC3482 in preparation of a medicine for treating premature ovarian failure. According to the invention, a mouse POI model is constructed through the induction of cyclophosphamide (CTX), and the MC3482 is proved to be capable of inhibiting the activity of SIRT5, reducing excessive macrophage infiltration of ovary caused by CTX, reducing M1 type macrophage activation and proinflammatory factor release, further inhibiting the apoptosis of ovarian granular cells, protecting follicular reserve and recovering ovarian functions. The invention clarifies the action effect and application scheme of MC3482 for preventing and treating POI, provides a new treatment strategy for chemotherapy-induced iatrogenic POI, and has important clinical transformation value.

The invention relates to the technical field of biological medicines, and discloses an application of a plant extract composition in preparation of a medicine for improving DNA damage of testicular spermatogenic cells, and the plant extract contains a herba epimedii extract and a rhizoma polygonati extract. The invention provides new application of the composition containing the herba epimedii extract and the rhizoma polygonati extract in preparation of the medicine for improving DNA damage of the testicular spermatogenic cells, the composition can remarkably improve the DNA damage of the testicular spermatogenic cells of mice caused by cyclophosphamide, recover the multiplication capacity of the mice, inhibit apoptosis of the mice and relieve spermatogenic function damage caused by cyclophosphamide, and the composition can be used for preparing the medicine for improving the DNA damage of the testicular spermatogenic cells of the mice. And the combined administration shows a synergistic effect instead of a simple additive effect, and the drug effect is obviously superior to that of any one of the epimedium extract and the rhizoma polygonati extract which are independently administered.

This invention discloses a plant-derived bactericidal composition and its application in fruit juice sterilization. The bactericidal composition consists of two plant-derived compounds with a synergistic effect, including phloretin and dodecylaldehyde, wherein the mass ratio of dodecylaldehyde to phloretin is (1-10):1. At room temperature and pressure, adding the bactericidal composition directly to fruit juice and maintaining it for 2 days can kill the vegetative cells and spores of *Bacillus cyclophosphamide*. This invention is non-toxic, harmless, simple, convenient, green, energy-saving, has high sterilization efficiency, and has no adverse effects on the nutrients and flavor of the fruit juice. This invention is highly effective in solving the problem of spoilage and deterioration of acidic fruit juice beverages caused by incomplete sterilization and spore killing.

This invention discloses the application of *Lactobacillus rhamnosus*-fermented ginseng freeze-dried powder in the preparation of immunomodulatory drugs, belonging to the field of bio-fermentation and immunomodulation technology. The *Lactobacillus rhamnosus*-fermented ginseng freeze-dried powder is prepared by fermenting ginseng with *Lactobacillus rhamnosus*. The rare ginsenosides include at least one of Ck, Rk1, Rh4, and Rg5. The immunomodulatory drug is used to improve cyclophosphamide-induced immunodeficiency. The amount of *Lactobacillus rhamnosus*-fermented ginseng freeze-dried powder added to the immunomodulatory drug is 10%-50% (mass fraction). The preparation method of the *Lactobacillus rhamnosus*-fermented ginseng freeze-dried powder is as follows: S1, ginseng pretreatment; S2, strain activation; S3, fermentation culture; S4, freeze-dried powder preparation. This invention has the technical effects of high bioavailability of ginseng active ingredients, significant immunomodulatory effect, good safety, and effective improvement of cyclophosphamide-induced immunodeficiency.

The application belongs to the field of new adjuvants and new dosage forms of pharmaceutical preparations, and particularly relates to a type I and type II immunogenic cell death inducer ion pairing engineered nanoassemblies as well as construction and application thereof. The nanoassemblies are composed of type I ICD inducers, type II ICD inducers, hydrophobic auxiliary counterions and amphiphilic lipid ion pairing. The type I ICD inducer is selected from mitoxantrone, doxorubicin, oxaliplatin or cyclophosphamide; the type II ICD inducer is selected from hypericin; and the hydrophobic auxiliary counterion is selected from cholesteryl sodium sulfate, cholic acid, deoxycholic acid, chenodeoxycholic acid, lithocholic acid, glycolcholic acid, taurocholic acid, glycochenodeoxycholic acid, taurochenodeoxycholic acid, deoxycholic acid lysine derivative, oleanolic acid and ursolic acid. The type I and type II ICD inducers are combined in the application, and have a synergistic tumor treatment effect.

The invention discloses a wolfberry-astragalus compound polysaccharide with an anti-myelosuppression effect as well as a preparation method and application of the wolfberry-astragalus compound polysaccharide. The wolfberry-astragalus compound polysaccharide is prepared by adopting a process of separately extracting wolfberry polysaccharide and astragalus polysaccharide and then mixing, the total sugar content is 70-80%, the uronic acid content is 10-14%, and the wolfberry-astragalus compound polysaccharide has specific molecular weight distribution and monosaccharide composition characteristics. Animal experiment results show that the wolfberry and astragalus compound polysaccharide can significantly improve peripheral hemopenia of myelosuppression mice induced by cyclophosphamide, promote recovery of the number of leukocytes, lymphocytes, monocytes and neutrophils, and effectively reverse weight loss caused by chemotherapeutic drugs. The wolfberry-astragalus compound polysaccharide provided by the invention is high in safety and remarkable in anti-myelosuppression effect, and can be used for preparing medicines or functional preparations for improving myelosuppression related diseases.

The invention discloses application of tremella aurantialba polysaccharide in preparation of a medicine for treating male immunological dyszoospermia, and belongs to the field of biological medicine. The invention provides a new application of tremella aurantialba polysaccharide, and experiments prove that the tremella aurantialba polysaccharide can improve dyszoospermia induced by cyclophosphamide, significantly increase the number of sperms of mice, reduce the abnormal rate of sperms and promote secretion of testosterone. According to the invention, cyclophosphamide is adopted to construct a male mouse dyszoospermia model, tremella aurantialba polysaccharides extracted in different manners are subjected to intragastric administration, the action mechanism of NAPs for improving mouse dyszoospermia is researched, the mechanism of NAPs for treating spermatogenesis is disclosed, and a basis is provided for clinical application.

This invention discloses the application of Polygonatum oligosaccharides in the preparation of products that improve sperm motility. The molecular weight of the Polygonatum oligosaccharides is 1 × 10⁻⁶. 4 ~5×10 4 This oligosaccharide, Da, can be prepared through steps including ethanol defatting, water extraction, 30%-50% ethanol precipitation, and protein removal. Experiments show that this oligosaccharide can significantly improve sperm motility, particularly restoring the forward sperm motility rate in asthenospermia model mice to over 32%, reaching the clinical treatment threshold; it can also effectively alleviate cyclophosphamide-induced reproductive damage and improve testicular tissue pathological damage. Furthermore, this oligosaccharide can upregulate the expression of sperm motility-related genes such as Crisp2 and Catsper, downregulate miR-27 expression, and has multiple effects including reducing oxidative stress, inhibiting inflammation, and improving reproductive hormone levels. Therefore, this oligosaccharide can be used to prepare products that improve sperm motility, prevent and / or treat asthenospermia, and alleviate chemotherapy-related reproductive damage.

The invention relates to a preparation method of a hippophae rhamnoides leaf isorhamnetin glycoside enriched solid beverage, and belongs to the field of functional plant beverage processing. The preparation method comprises the following steps: preparing sea buckthorn green tea and sea buckthorn green tea freeze-dried powder by taking sea buckthorn leaves as a main raw material; carrying out ethanol extraction and AB-8 type macroporous resin separation and purification to obtain an isorhamnetin glycoside substance enriched component; a Maillard composite system formed by whey protein isolate and maltodextrin is loaded with an isorhamnetin glycoside substance enrichment component, the isorhamnetin glycoside substance enrichment component is compounded with sea buckthorn green tea freeze-dried powder, freeze drying is performed, and the isorhamnetin glycoside enrichment solid beverage is obtained. The isorhamnetin glycoside enriched solid beverage disclosed by the invention has good solubility, and shows a remarkable immunological enhancement effect in a cyclophosphamide induced immunocompromised mouse model. The method has a wide application prospect in the aspects of high-value utilization of hippophae rhamnoides leaf resources and functional beverage development.